GWLL · XBRL financial data

Goldenwell Biotech financial statements, every quarter

The same tables from 15 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal quarters (GWLL's year ends in late December)

In thousands of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Revenue	—	year only	0	0	0	0	0	0	0	0	0	0
Revenue from contracts with customers	0	0	0	0	0	—	—	—	—	—	—	—
Cost of revenue	0	0	0	0	0	0	0	0	0	0	0	0
Gross profit	0	0	0	0	0	0	0	0	0	0	0	0
General and administrative	36	21	31	50	23	25	36	28	26	23	31	35
Total operating expenses	36	21	(31)	50	23	25	36	28	26	23	31	35
Operating income (loss)	(35)	(21)	(31)	(50)	(23)	(25)	(36)	(28)	(26)	(23)	(31)	(35)
Interest expense	—	year only	2	2	2	2	2	2	2	2	2	—
Other income (expense)	—	—	—	—	—	—	—	—	—	—	16	—
Income tax expense (benefit)	0*	0*	0	0	0	0	0	0	0	0	0	0
Net income (loss)	(35)	(21)	(31)	(50)	(23)	(27)	(39)	(30)	(28)	(200)	(18)	(37)
Earnings per share, diluted USD per share	—	—	0.00	—	—	0.00	0.00	—	—	0.00	0.00	0.00
Weighted average shares, diluted thousands of shares	—	—	99,000	96,433	96,433	99,000	99,000	96,433	96,433	99,000	99,000	99,000

Fiscal quarters (GWLL's year ends in late December)

In thousands of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Cash and cash equivalents	12	53	24	26	5	49	17	77	46	27	13	11
Inventory	175	175	175	175	175	175	175	175	175	175	0	0
Right-of-use asset	0	0	0	0	0	0	0	0	0	0	0	0
Total assets	187	228	199	200	179	224	192	267	234	36	19	29
Accounts payable	—	0	0	0	0	0	0	0	0	0	0	0
Accrued liabilities	—	—	—	—	—	0	—	8	0	—	0	0
Total current liabilities	—	—	—	—	—	2	—	110	102	102	100	100
Long-term debt	—	46	—	—	—	174	176	—	—	—	—	—
Total liabilities	81	143	145	197	199	271	278	383	378	380	380	427
Accumulated deficit	(1,207)	(1,228)	(1,259)	(1,309)	(1,332)	(1,360)	(1,398)	(1,428)	(1,456)	(1,656)	(1,674)	(1,711)
Total stockholders' equity	106	85	54	4	(19)	(47)	(86)	(116)	(144)	(344)	(361)	(398)
Total liabilities and equity	187	228	199	200	179	224	192	267	234	36	19	29
Common shares outstanding (cover page) thousands of shares	99,000	99,000	99,000	99,000	99,000	99,000	99,000	99,000	99,000	99,000	99,000	99,000

Fiscal quarters (GWLL's year ends in late December)

In thousands of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Net income (loss)	(35)	(21)	(31)	(50)	(23)	(27)	(39)	(30)	(28)	(200)	(18)	(37)
Net cash from operating activities	(35)	(21)*	(31)	(50)	(23)*	(19)*	(32)	59	(31)*	(19)*	(13)	(47)*
Proceeds from issuing common stock	0*	0*	0	0	0*	—	0	0	0*	—	0	0*
Proceeds from long-term debt	30	86*	0	49	0*	70*	0	0*	0*	—	0	0*
Net cash from financing activities	30	62*	2	51	2*	64*	0	0	0*	0*	0	45*

SIC 2000 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2000 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Goldenwell Biotech	11	0	(47)*	99.0M	0.2 quarters	Q2 FY26 10-QJun 30, 2026
BranchOut Food	0	4,458	(2,788)*	15.3M	—	Q2 FY26 10-QJun 30, 2026
Borealis Foods	500	7,782	(123)	21.5M	4.1 quarters	Q1 FY26 10-QMar 31, 2026
Sow Good	8.5	not reported	(2,607)*	20.1M	0.0 quarters	Q2 FY26 10-QJun 30, 2026
Laird Superfood	22,969	41,294	1,451*	11.2M	—	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.